We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Chemical Name: 11β-[4-dimethylamino] phenyl-17β-hydroxy-17-(1-propynyl) estra-4, 9-dien-3- one)
Molecular Formula: C29H35NO2
Molecular Weight: 429.61
Drug Specifications：
25mg
Drug application：
[Dosage and Administration]
Take within 72 hours following unprotected sexual life or contraception failure. The earlier the drug is taken, the better pregnancy-preventing effect will be obtained. Take orally 25 mg(1 tablet) on an empty stomach or 2 hours after eating. Do not eat for 1-2 hours after taking the drug.
[Precautions]
1. Women to take this drug should have had at least one normal flow before the current cycle; the emergency contraceptive method may be employed only after the first unprotected sexual life in the current cycle.
2. Unprotected sexual life is not allowed after use of this drug and prior to menstruation recovery in the current cycle. Effective contraceptive measures are required for sexual life again.
3. This drug is for emergency contraception and does not have the function of abortion.
4. This drug must not be used as a routine contraceptive taken after each sexual life or each month and may only be used as a remedial measure against contraception failure.
5. If contraception using this drug as an emergency contraceptive fails, pregnancy termination is suggested.
Eighteen years of qualification
Audited Supplier
Pharma Sources Insight JANUARY 2024
